Yes, an FDA-approved mesenchymal stromal cell therapy exists. FDA announced Ryoncil's approval on December 18, 2024 for steroid-refractory acute graft-versus-host disease in pediatric patients aged two months and older. That is a specific product, disease setting and age range—not regulatory approval of “stem cells” as a universal treatment. 1
The distinction cuts in both directions. Saying no such approved therapy exists can be outdated. Saying that this approval validates a different clinic's injections can be equally misleading.
What Ryoncil actually is
Ryoncil, or remestemcel-L-rknd, contains mesenchymal stromal cells from healthy adult donors' bone marrow. The approved use concerns a serious complication in which graft-derived immune cells attack the recipient's tissues after a transplant and the disease has not responded adequately to corticosteroid treatment. 1
FDA's product record names the therapy and the pediatric indication. It does not provide a general authorization to treat aging, arthritis, diabetes, brain injury or unrelated problems with any preparation described as MSCs. 2
What “70% response” means
The prescribing information describes a multicenter, prospective, single-arm study: 55 enrolled and 54 treated. At day 28, 38 of 54 treated patients had an overall response: 16 complete and 22 partial responses. The overall percentage rounds to 70%; the separately rounded 30% and 41% components need not add to exactly 70%. 3
| Recorded result | What it does not establish |
|---|---|
| 38/54 overall responses at day 28 | That 70% were permanently cured |
| 16 complete responses at that assessment | That later relapse or other complications were impossible |
| Single-arm treatment study | A randomized estimate of superiority over another treatment |
The label gives a median duration of response of 54 days for the specified response analysis. Its definitions and follow-up belong with the percentage. The day-28 assessment is not a substitute for a survival result. 3
This does not dismiss a result in a severe disease. It preserves the clinical question the result actually answers. A headline can accurately report the response without assigning it an unsupported lifetime meaning.
The safety information belongs beside the benefit
FDA lists concerns including infusion and allergic reactions, potential infectious-agent transmission, and ectopic tissue formation. Infections and other adverse reactions are part of the product's safety record. Approval does not mean the cells are inherently harmless because they are biological. 1
This article is not a treatment-selection or administration guide. Clinicians must use the actual current product information and the person's medical circumstances.
Why an older FDA alert can confuse the search results
A July 2020 FDA consumer alert discusses unapproved regenerative products. Its statement about which stem-cell products were approved reflected that earlier period. It should not be quoted as an exhaustive September 2026 inventory after later approvals such as Ryoncil. 4 2
The correct repair is not to discard the alert's warning or to transfer approval to the entire industry. It is to date the warning and check the exact later product record. We retain the old source as historical context, not current proof that approved MSC treatment does not exist.
How a clinic claim can outrun the evidence
Consider this fictional advertisement: “MSC therapy is FDA approved, so our regenerative infusion is approved too.” The missing information is the identity of the product and whether the actual offered use matches its authorization. A category label does not establish those links.
Before accepting the conclusion, the record would need to connect the named product, manufacturer, clinical use and regulatory decision. A third-party clinic cannot establish that chain simply by linking to a different manufacturer's approval announcement.
The same discipline applies to testimonials and case reports. An account of improvement can motivate investigation, but it cannot change the population and indication written in a regulator's decision. See approved, cleared and registered for the different meanings of those terms.
Why this belongs in a medical-progress publication
Ryoncil is a concrete example of cell therapy reaching a specific clinical use. That makes it more informative than an undifferentiated list of “stem-cell breakthroughs.” It also illustrates why a useful archive must retain product identity and dates.
For a separate cell-replacement problem, our islet-therapy comparison follows diabetes programs. It does not borrow Ryoncil's response rate, approval or safety record. Progress in one field is worth reporting without turning it into a promise for every other field.